NYXH Share Price Performance
€0
-5.63 (-100.00%)
Price €0
Fair Value€2.50
Share Pricen/a
Analysis Article • Aug 08
Nyxoah SA Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
NYXH Community Narratives
AN
Fair Value
·Fair Value €2.5 43.9% undervalued intrinsic discount
Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €5.8 75.8% undervalued intrinsic discount
FDA Approval And Expanding Network Will Grow US Sleep Market
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value €8.3 83.1% undervalued intrinsic discount
Minimally Invasive Devices Will Capture Expanding Sleep Market
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery
Nyxoah’s sleep apnea implant looks well timed as more people get diagnosed and demand grows for alternatives to bulky machines, but the U.S. rollout may move slower than many expect. Regulatory reviews, insurance coverage decisions, and intensifying competition could keep losses high and squeeze pricing before the business has a chance to scale.Read more
AN
€2.5
43.9% undervalued intrinsic discount
Fair Value
Profit Margin
3.48%
Future PE
34.82x
Price in 2029
€2.32
Minimally Invasive Devices Will Capture Expanding Sleep Market
A small medical device company is betting that its Genio implant can make sleep apnea treatment easier for more patients, helping it win over busy U.S. clinics as diagnosis rates rise. The upside is tied to smooth approvals and insurance coverage, but a single-product business and ongoing legal and competitive pressure could quickly derail the story.Read more
AN
€8.3
83.1% undervalued intrinsic discount
Fair Value
Profit Margin
4.92%
Future PE
64.21x
Price in 2029
€7.73
FDA Approval And Expanding Network Will Grow US Sleep Market
Nyxoah has fresh U.S. approval for its Genio implant and is building a fast-growing network of doctors and sleep centers that could help more people move beyond CPAP therapy. But bigger rivals are pushing back, and legal fights, reimbursement delays, and heavy spending could slow the rollout before the business can stand on its own.Read more
AN
€5.8
75.8% undervalued intrinsic discount
Fair Value
Profit Margin
4.92%
Future PE
56.24x
Price in 2029
€5.41
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
NYXH: U.S. Launch Execution And Capital Access Will Drive Future Upside
Fair Value: €2.5 43.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NYXH: Funding Progress And Execution Milestones Will Underpin Long Term Upside
Fair Value: €8.3 83.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NYXH: Capital Raise Will Support Execution Of 2026 Revenue Guidance
Fair Value: €5.8 75.8% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nyxoah SA Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
- -0.96
- 60.19%
- -443.17%
- 69.9%
About NYXH
- Founded
- 2009
- Employees
- 154
- CEO
- WebsiteView website
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
